Bacterial cultivation system, 9/17
September 2017—Advanced Instruments displayed its newly launched Anoxomat III at the 69th AACC Annual Scientific Meeting and Clinical Lab Expo in San Diego.
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Ultra-sensitive POC test for GFAP, 9/17
September 2017—Dx-Sys has developed an ultra-sensitive, lateral flow point-of-care diagnostic test for glial fibrillary acidic protein, a potential biomarker for traumatic brain injury.
MDxHealth collaborations, 8/17
August 2017—MDxHealth has signed an exclusive licensing deal with Ghent University, Belgium, for its proprietary molecular diagnostic visualization technology that will allow the visual detection of epigenetic changes associated with cancer in tissue and liquid specimens.
Multigene panel testing for hereditary cancer risk, 8/17
August 2017—Myriad Genetics announced results from Study 005, a large 2,000 patient prospective study of the Myriad myRisk Hereditary Cancer test, which were featured in three poster presentations at the American Society of Clinical Oncology annual meeting in June.
SeraCare releases v2 NGS QC software , 8/17
August 2017—SeraCare Life Sciences launched iQ NGS QC Management v2, data management software that supports whole-workflow data capture from sample preparation to variant calling along with associated reagent and operator data. The software enables laboratories to re-create their QC workflows, set up their critical quality control metrics in the software, and have the data imported automatically using the new iQ Connector API—all to provide real-time insights into performance.
Molecular assay for C. diff, 8/17
August 2017—Quidel received 510(k) clearance to market its Solana C. difficile Assay for the direct, qualitative detection of Clostridium difficile DNA in unformed stool specimens of patients suspected of having Clostridium difficile infection.
Stago acquires HemoSonics, 8/17
August 2017—The Stago group has completed the acquisition of HemoSonics LLC, a company that develops point-of-care testing solutions and is based in Charlottesville, Va., with facilities in Durham, NC.
Vitros NephroCheck test for AKI gets CE mark, 8/17
August 2017—Ortho Clinical Diagnostics launched its Vitros NephroCheck test, a fully automated risk assessment tool for predicting acute kidney injury. The test has received CE mark clearance and is available for purchase in Europe and for use on Ortho’s Vitros Systems.
Antimicrobial testing standards, 8/17
August 2017—The Clinical and Laboratory Standards Institute has published a revised edition of “M100: Performance Standards for Antimicrobial Susceptibility Testing, 27th ed.,” its annual supplement that provides revised breakpoints, new testing recommendations, and reporting changes needed to incorporate into routine practice.
Improved urinalysis control, 8/17
August 2017—Streck UA-Cellular Complete, a comprehensive cellular and chemistry analyte urinalysis control, is an integrated urinalysis control for the Siemens Clinitek Atlas/Sysmex UF-1000i and Arkray Aution Hybrid AU-4050 integrated systems. UA-Cellular Complete features true cellular components (no latex or other synthetic material) and provides three concentrations of combined urinalysis control to represent the various patient sample scenarios.